Sanofi (SNY)
| Market Cap | 112.48B |
| Revenue (ttm) | 51.60B |
| Net Income (ttm) | 6.00B |
| Shares Out | 2.32B |
| EPS (ttm) | 2.34 |
| PE Ratio | 24.71 |
| Forward PE | 11.14 |
| Dividend | $2.04 (4.19%) |
| Ex-Dividend Date | May 9, 2024 |
| Volume | 513,920 |
| Open | 48.61 |
| Previous Close | 48.82 |
| Day's Range | 48.31 - 48.67 |
| 52-Week Range | 42.63 - 55.72 |
| Beta | 0.45 |
| Analysts | Hold |
| Price Target | 55.00 (+13.01%) |
| Earnings Date | Apr 25, 2024 |
About SNY
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines... [Read more]
Financial Performance
In 2023, Sanofi's revenue was 46.44 billion, an increase of 2.32% compared to the previous year's 45.39 billion. Earnings were 5.40 billion, a decrease of -35.49%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to one analyst, the rating for SNY stock is "Hold" and the 12-month stock price forecast is $55.0.
News
Novavax stock jumps 50% as Sanofi deal kicks off turning point for struggling vaccine maker
Novavax said the deal with Sanofi allows it to remove its "going concern" warning, which it first issued last year due to doubts about staying afloat.
Sanofi to Spend $1 Billion to Boost Drug Production in France
Sanofi said the bulk of the investment will double capacity of monoclonal antibody production, which are key in developing an array of pharmaceuticals, at its Vitry-sur-Seine site.
Sanofi pledges new 1 bln euros worth of investments in French production sites
Sanofi on Monday announced it would invest over 1 billion euros ($1.1 billion) to create new medicines and vaccine production capacities at three of its French sites.
Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty
Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty Paris, May 13, 2024. As the largest private contributor to ...
Novavax Surges on $1.2 Billion Sanofi Vaccine Deal
Novavax shares soared after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Madison Muller reports on Bloomberg Televi...
Novavax (NVAX) Deal with Sanofi to Co-Commercialize Covid Vaccine
Novavax (NVAX) signed a deal with drugmaker Sanofi to co-commercialize the Covid Vaccine. Diane King Hall discusses this, as well as Novavax's 1Q earnings.
Novavax stock soars on $1.2 billion Sanofi vaccine deal
Novavax (NVAX) shares are skyrocketing after announcing a $1.2 billion deal with Sanofi (SNY) to commercialize a combined COVID-19 and flu shot. Yahoo Finance's Anjalee Khemlani joins The Morning Brie...
Novavax Stock Doubles on $1.2B Sanofi Deal for COVID-19, Flu Vaccines
Novavax (NVAX) shares more than doubled in intraday trading Friday after announcing a $1.2 billion deal to license its vaccine technology to French drugmaker Sanofi (SNY).
Novavax Gets $1.4 Billion Deal With Sanofi. The Stock Jumps.
The two companies will also work on a shot that combines Covid-19 and flu vaccines.
Novavax shares jump 40% on $1.2 billion licensing deal with Sanofi despite Q1 losses
Novavax (NASDAQ:NVAX) shares rocketed 40% in premarket trading Friday, driven not only by the company's fiscal Q1 2024 earnings report but more significantly, by a crucial multi-billion dollar deal wi...
Novavax shares surge on new $1.4 billion deal with Sanofi
Novavax on Friday said it had struck a $1.4 billion deal with Sanofi to commercialize its existing COVID-19 vaccine and develop a new combined jab to inoculate against both the coronavirus and influen...
Novavax Reports First Quarter 2024 Financial Results and Operational Highlights
Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's...
France's Sanofi in COVID-19 vaccine deal with Novavax - statement
Sanofi on Friday announced it has reached a 'co-exclusive' licensing agreement with Novavax to sell a stand-alone COVID-19 vaccine and develop new flu-COVID-19 combination vaccines.
Novavax signs multibillion-dollar deal with Sanofi to commercialize Covid vaccine, develop combination shots
The deal will allow Novavax to lift its "going concern" warning, which it first issued in 2023 due to having "substantial doubt" about its ability to survive.
Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines
Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards Provides Novavax with cash and an equ...
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inhibrx, Inc. (N...
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations
Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respirator...
Press Release: Annual General Meeting of April 30, 2024
Annual General Meeting of April 30, 2024 Approval of the financial statements for the fiscal year 2023 Distribution of a cash dividend of €3.76 per share, with payment as of May 15, 2024 Board composi...
Sanofi CEO Paul Hudson on Q1 results: Hope to gather even more momentum later this year
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, drug pipeline outlook, and more.
Sanofi Sales, Profit Beat Forecasts
Sanofi backed its full-year earnings guidance after it reported first-quarter profit ahead of consensus, with sales growth driven by continued strength in anti-inflammatory drug Dupixent and its new d...
Sanofi Q1 profit slips on generic competition, forex effects
Sanofi's said on Thursday first-quarter operating income declined 14.7% as unfavourable currency effects and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of anti-inflam...
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER and business EPS (1) of €1.78 Dupixent sales up 24.9% to €2,835 mil...
FTC looking to accelerate inquiry into prescription-drug middlemen, chair says
The Federal Trade Commission is working to accelerate its inquiry into the prescription-drug middlemen known as pharmacy-benefit managers, while also expanding its scrutiny of drug patents that can ke...
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of rilz...